Sabinsa received the coveted 2009 Thomas Alva Edison Patent Award in the Nutraceuticals Category for the patent on its proprietary product, GarCitrin®. The patent, US 7063861, is entitled "Bioavailable Composition of Natural and Synthetic HCA."
The Thomas Alva Edison Patent Awards were presented by the Research and Development Council of New Jersey at the Council’s annual fall dinner, held at the Liberty Science Center on November 5th. For nearly 20 years a small group of researchers, engineers, inventors and industry professionals have worked to create a higher-level of public awareness of the many outstanding New Jersey inventors that have impacted society.
"We are honored to receive the 2009 Thomas Alva Edison Patent Award," said Sabinsa founder Dr. Muhammed Majeed. "We have long held the belief that science and innovation can benefit human nutrition, and it is gratifying to have that commitment validated by this distinguished organization."
GarCitrin® is a patented natural extract combining the weight management benefits of hydroxycitric acid (HCA) with the bioavailability-enhancing effects of garcinol, a polyisoprenylated benzophenone isolated from Garcinia cambogia and Garcinia indica. Garcinol enhances the biological action of HCA and contributes antioxidant activity to the composition. Sabinsa has done a human clinical study to show GarCitrin® is statistically significant in reducing total body weight and reducing body fat.
This is not the first time Sabinsa has been honored with an Edison Patent Award. In 2005 Sabinsa received an award for its Cosmoperine® product – which promotes absorption of actives through the skin, and for ForsLean® in 2004 – the flagship ingredient of Sabinsa recognized world over for increasing lean body mass in the weight management category.
For more information on GarCitrin, visit www.garcitrin.com.
